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Abstract: Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved 
by the US Food and Drug Administration in February 2011 for the management of chronic 
obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the 
terms “roflumilast” and “COPD”. Reference citations from publications identified were also 
reviewed. All articles published in English using the terms “roflumilast” and “COPD” were 
retrieved. For evaluation of clinical efficacy, published Phase III studies and pooled analyses 
of Phase III trials were included. In seven published Phase III trials, roflumilast at 500 μg daily 
showed improvements in lung function as measured by pre- and post-bronchodilator forced 
expiratory volume in 1 second. Roflumilast appears to be useful in vulnerable patients who are 
at high risk for exacerbations. Roflumilast was found to be effective when administered alone 
and with concomitant long-acting bronchodilator therapy in the Caucasian and Asian popula-
tion. Patients with severe-to-very severe COPD, chronic bronchitis, and frequent history of 
exacerbations derived the greatest benefit with roflumilast. Compared to the standard of care 
therapies, roflumilast is more cost-prohibitive. Roflumilast was well tolerated, with the most 
common adverse events observed in clinical trials being diarrhea, nausea, and headache. Weight 
loss and increased risk of psychiatric events have also been observed with roflumilast in clinical 
trials. Roflumilast is a safe and effective option for the treatment of COPD.
Keywords: roflumilast, COPD, phosphodiesterase-4 inhibitor
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) has been increas-
ing over the last few decades and is a leading cause of morbidity and mortality   
worldwide.1 It was the sixth leading cause of death in 1990 and is expected to be the 
third leading cause of death by 2020. Acute COPD exacerbations are a leading cause 
of hospitalizations, associated with US$29.5 billion in direct costs. The Global initia-
tive for chronic Obstructive Lung Disease (GOLD) guidelines state that the strongest 
predictor for future exacerbations is a history of previous exacerbations.1 In addition, 
COPD commonly develops in middle-aged, long-time smokers, who may present 
with other comorbidities such as cardiovascular disease, osteoporosis, and skeletal 
muscle dysfunction.1 Such comorbidities may occur at any degree of airflow limitation. 
Moreover, worsening airflow limitation contributes to a higher risk for exacerbation 
and mortality, making these high-risk patients a vulnerable population.
The updated GOLD guideline classifies patients into four groups of severity based 
on spirometry, symptom severity, and exacerbation risk. Based on the severity of illness, 
several pharmacologic options are available to manage COPD. These include broncho-
dilators (beta-2 agonists, anticholinergics, and methylxanthines) and anti-inflammatory 
agents (inhaled and oral corticosteroids). In addition to the severity of illness, comor-
bidities need to be considered when developing a pharmacologic plan for the patient. 
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Lung function and symptoms improve with the use of these 
agents, and they may potentially reduce hospitalizations.1 
However, these pharmacologic agents are not devoid of 
adverse effects and may worsen comorbid conditions. The 
phosphodiesterase (PDE)-4 inhibitor roflumilast (Daliresp® 
or Daxas®) is a novel treatment alternative which targets 
inflammatory cells responsible for the progressive and per-
sistent airflow limitation associated with COPD. This review 
article will evaluate the pharmacology, pharmacokinetics, 
and clinical efficacy and safety of roflumilast in vulnerable 
COPD patients. Literature was retrieved through PubMed 
using the terms “roflumilast” and “COPD”. Reference cita-
tions from publications identified were also reviewed. All 
articles published in English using the terms “roflumilast” 
and “COPD” were retrieved.
Vulnerable patients and COPD
Approximately 30% of patients with COPD present with 
coexisting heart failure.2 In a prospective randomized trial, 
lung function in 107 patients with heart failure and COPD 
was compared to that of 377 patients with heart failure and 
no COPD.3 All patients’ spirometric values were evaluated 
and reported as follows: forced expiratory volume in 1 second 
(FEV1) was 65% of the predicted value (95% confidence 
interval [CI]: 63%–67%); forced vital capacity (FVC) was 
71% of predicted (95% CI: 69%–72%); and FEV1/FVC was 
0.72 (95% CI: 0.71–0.73). All three of these indicators were 
strong predictors of all-cause mortality in these patients. 
Patients with moderate-to-severe COPD had a shorter survival 
rate when compared with patients without COPD or with mild 
COPD (P=0.004). As there is an overlap of common symp-
toms such as breathlessness with COPD and heart failure, 
patients with these conditions may not be optimally treated. 
This may place patients at risk for negative outcomes.
Since patients commonly present with concomitant 
cardiovascular disease, beta-blockers may be a part of their 
therapeutic regimen.4,5 Beta-blockers have been shown to be 
beneficial in cardiac disease. However, in patients with COPD, 
nonselective beta-blockers may be life-threatening due to 
bronchoconstriction.6 Three recent studies investigated the 
safety of beta-1-selective antagonists in patients with COPD. 
The first study was a Cochrane Review which assessed the 
effect of beta-1-selective antagonists on FEV1 at rest in patients 
with COPD versus placebo.7 It was found in 22 randomized, 
blinded, controlled studies (eleven single-dose treatment and 
eleven long-term treatment) that beta-1-selective antagonists 
produced no difference in FEV1 or resulted in adverse respira-
tory effects. This was consistent in patients with either severe 
or reversible obstruction. A second randomized, placebo-
controlled, crossover trial investigated the effects of beta-1
-selective antagonists on dynamic hyperinflation in patients 
with moderate-to-severe COPD.8 The investigators compared 
bisoprolol to placebo and assessed the extent of dynamic 
hyperinflation at peak isotime during a two-cycle endurance 
test. Peak isotime was defined as the latest time point that was 
reached during the exercise test. Although bisoprolol resulted 
in modest worsening of dynamic hyperinflation, exercise 
duration did not change with moderate-to-severe COPD. 
The investigators concluded that the effect on hyperinflation 
was small and should not be a contraindication for bisoprolol 
therapy in COPD. Lastly, a retrospective cohort of patients 
hospitalized for acute COPD exacerbation with concomitant 
therapy for ischemic heart disease or congestive heart failure 
were used in a study to evalutate effects on hospital mortal-
ity, 30-day readmission, and late mechanical ventilation.9 The 
investigators showed that there was no association between 
beta-1-selective antagonist therapy and the three endpoints 
studied. Therefore, continuing beta-1-selective antagonists 
appears to be safe in hospitalized patients with COPD and 
concomitant heart failure OR ischemic heart disease. 
Osteoporosis is another common comorbid condition in 
patients with COPD.1 Systemic inflammation secondary to 
moderate-to-severe COPD may lead to osteoporosis.10 Three 
studies have assessed the effect of inhaled corticosteroids 
(ICS) (triamcinolone, budesonide, and fluticasone) on bone 
mineral density in patients with COPD.11–13 Although tri-
amcinolone was associated with a decrease in bone mineral 
density at 3 years from baseline, bone mineral density did 
not change with inhaled fluticasone and budesonide. On the 
other hand, a significant risk of osteoporosis with systemic 
corticosteroids has been established.
In addition, prolonged oral corticosteroid use may result 
in peripheral and respiratory muscle weakness. One study 
investigated 21 patients admitted for asthma or COPD exacer-
bation requiring dose escalation of oral corticosteroids.14 The 
study found that patients with COPD or asthma had respira-
tory and peripheral muscle weakness attributed to treatment 
with even low doses of corticosteroids. The outcome of 
muscle weakness was independent of airflow obstruction.   
A second study investigated eight patients with COPD and 
concomitant steroid-induced myopathy compared to control.15   
Patients with steroid-induced myopathy had greater periph-
eral and ventilatory muscle weakness compared to control 
(P0.001). Patients in the steroid-induced myopathy group 
had a decreased survival rate compared to control patients, 
with a similar level of airflow limitation (P0.025).Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Safety and special dosing 
considerations
In clinical trials involving 4,438 patients with COPD, the 
most common adverse events with roflumilast were diarrhea 
(9.5%), weight loss (7.5%), nausea (4.7%), and headache 
(4.4%). Rates of discontinuation due to adverse events were 
14.8% with roflumilast and 9.9% with placebo, most com-
monly due to diarrhea and nausea.16
Weight loss is common in patients with severe COPD 
and is an independent risk factor for mortality.1 The exact 
mechanism is not known, but is thought to be due to fat 
loss, as PDE is involved in lipolysis.17 Weight loss was 
reported in 7.5% compared to 2.1% in the roflumilast and 
placebo groups, respectively, with an average weight loss of 
2 kg.1,16 In a pooled analysis, patients experiencing gastro-
intestinal effects had greater weight loss, particularly in the 
first 6 months.18 Therefore, this drug should be avoided in 
underweight patients.1
Psychiatric events such as insomnia, anxiety, and depres-
sion have been observed more commonly with roflumilast.16 
Three patients attempted suicide, with one of the three 
completing suicide, in clinical trials. Caution is advised in 
patients with a history of depression and/or suicidal behavior 
or thoughts.
Roflumilast 250 μg once daily was studied in patients with 
hepatic impairment for 14 days.19 There were eight patients 
in each classification (Child-Pugh class A, B and healthy 
subjects).  Results showed the area under the curve (AUC) of 
roflumilast increased by 51% and roflumilast N-oxide by 24% 
with mild impairment (Child-Pugh class A). Similarly, there 
was an increase in roflumilast and roflumilast N-oxide of 92% 
and 41%, respectively, in Child-Pugh class B patients. In addi-
tion, there was an increase in Cmax of roflumilast and roflumi-
last N-oxide of 2% and 26%, respectively, in Child-Pugh class 
A and of 27% and 40%, respectively, in Child-Pugh class B.   
The manufacturers of roflumilast do not recommend its 
use in patients with Child-Pugh class B and C.16 Further, a 
dose of 500 μg has not been studied in patients with hepatic 
impairment.
In addition, roflumilast 500 μg was investigated in 
12 patients with severe renal impairment, defined as a 
creatinine clearance 30 mL/min.20 In patients with renal 
impairment, roflumilast’s AUC and Cmax concentrations 
were decreased by 20% and 16%, respectively, compared to 
healthy subjects. Roflumilast N-oxide’s AUC and Cmax were 
also decreased, by 16% and 12%, respectively, in patients 
with renal impairment compared to healthy subjects. Half-
life concentrations of roflumilast and roflumilast N-oxide 
increased by 19% and 30%, respectively, in patients with 
severe renal impairment versus healthy subjects. Therefore, 
no dosage adjustments are needed for patients with renal 
impairment.16
Overview of pharmacology
Eleven PDEs make up the PDE super-family and are respon-
sible for various biologic functions.21 PDE-4 inactivates sec-
ondary messenger cyclic adenosine monophosphate found in 
proinflammatory and immune-competent cells in the lungs. 
Roflumilast and its active metabolite (roflumilast N-oxide) 
are selective PDE-4 inhibitors that result in anti-inflammatory 
effects by preventing the breakdown of cyclic adenosine 
monophosphate, allowing it to activate protein kinase A.16,17 
Inhibition of fibrotic lung remodeling and decreased oxida-
tive stress are achieved by reducing the release of inflamma-
tory mediators from neutrophils, monocytes, and cytokines 
from CD-8 and CD-4 T-cells. In healthy subjects, it has 
been demonstrated that roflumilast may reduce the number 
of neutrophils, other inflammatory cells, and inflammatory 
markers in the sputum and bronchial airways.22,23
The absolute bioavailability of roflumilast following oral 
administration is 79%.24 The time of peak plasma concentra-
tions is about 1 hour, while steady-state concentrations are 
achieved in about 3 to 4 days following once-daily dosing. 
Roflumilast exhibits a linear and predictable pharmacokinetic 
profile over doses ranging from 250 to 1,000 μg.17
Roflumilast is rapidly metabolized to an active metabolite, 
roflumilast N-oxide, via CYP3A4 and CYP1A2 metabolism. 
Roflumilast N-oxide accounts for approximately 90% of the 
total PDE-4 inhibitory activity and exhibits similar potency 
and specificity to the parent compound.17 Peak plasma con-
centrations of the active metabolite are reached in 8 hours, and 
steady-state plasma concentrations are reached within 6 days. 
Approximately 70% of roflumilast is excreted renally.
Administration of roflumilast in a non-fasting state reduces 
the Cmax and time to peak plasma concentration of the parent 
compound by 40% and 1 hour, respectively, in healthy sub-
jects.25 Roflumilast N-oxide, which is primarily responsible for 
pharmacological activity, is not affected by a fasting or non-
fasting state. Therefore, roflumilast can be taken with or with-
out food.16 Roflumilast is highly protein bound (99%), with a 
half life of 17 hours. Steady state concentrations are achieved 
at 3–4 days. It is metabolized by CYP3A4 and CYP1A2 to 
roflumilast N-oxide. It is renally eliminated. Roflumilast 
N-oxide is also highly protein bound (97%) with a half life of 
30 hours. Steady state concentrations are reached at 6 days. It 
is metabolized by CYP3A4 and renally eliminated.16Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Clinical efficacy
Roflumilast was evaluated for clinical efficacy in seven Phase 
III, randomized, double-blind, placebo-controlled, multicenter 
trials as monotherapy and in combination therapy in patients 
with varying degrees of COPD severity (Table 1).18,26–29 
Three of the seven trials showed that roflumilast significantly 
increased FEV1 compared to placebo.26–28 Rates of exacerba-
tion were also significantly lower in the roflumilast arm. There 
are several limitations to the above trials. The first trial’s short 
duration makes it difficult to determine long-term improve-
ments in lung function, health-related quality of life, and 
exacerbation rates.26 As well, patients were unable to continue 
long-acting maintenance medications, therefore roflumilast’s 
effectiveness in addition to maintenance medications could 
not be assessed. Similarly to the first trial, patients taking long-
term bronchodilator therapy in the second trial and patients 
taking concomitant ICS in the third trial were excluded.27,28 
Therefore, the clinical significance of adding roflumilast 
in patients with severe or very severe disease is difficult to 
ascertain, as such patients are more likely to be taking long-
term bronchodilator therapy in addition to ICS.
A post hoc pooled analysis of the 2007 trial combined 
with a previously unpublished study evaluated a total of 2,690 
patients with chronic bronchitis with or without emphysema, 
or those taking concomitant ICS or using short-acting anti-
cholinergics, and with high cough or sputum scores. In this 
study, roflumilast showed a trend toward reducing exacerba-
tion rates in patients.18
Two Phase III, 6-month, randomized, double-blind,   
placebo-controlled, multicenter trials assessed the benefit of 
adding roflumilast to long-acting bronchodilators in patients 
with moderate-to-severe COPD.29 In the first study, 933 patients   
were randomized to receive roflumilast 500 μg plus salme-
terol (long-acting beta agonist [LABA]) or placebo plus 
salmeterol, while 743 patients in the second study were 
randomized to receive roflumilast 500 μg plus tiotropium or 
placebo plus tiotropium. FEV1 improved significantly com-
pared to placebo in both trials. Rates of exacerbations were 
not significantly different in either of the studies; however, 
the proportion of patients experiencing moderate or severe 
exacerbations was significantly reduced in the salmeterol 
study but not in the tiotropium study. Limitations of this 
study include the short duration and insufficient power to 
assess secondary outcomes. In addition, a majority of the 
patients in both studies had moderate COPD and thus were 
at a lower risk for exacerbations.
An additional prespecified pooled analysis in 3,091 
patients with a frequent exacerbation history was conducted 
to assess the efficacy of roflumilast used concomitantly with 
LABA in reducing exacerbation frequency.30 Mean rate of 
exacerbations was significantly reduced regardless of LABA 
use. Roflumilast also significantly reduced mean rate of 
exacerbations regardless of exacerbation history. The main 
limitation of this study is that it cannot be extrapolated to 
those patients on concomitant LAACs. Additionally, sub-
group analyses regarding exacerbation frequency were not 
prespecified, and outpatient records documenting exacerba-
tions may have been incomplete.
Roflumilast 500 μg once daily was compared to placebo 
in 410 Asian patients over 12 weeks.31 Roflumilast signifi-
cantly improved FEV1 in patients with moderate-to-severe 
COPD. The treatment was well tolerated in this population. 
Further, the adverse effects were similar to those found in the 
Caucasian population. In another recent study, the efficacy 
and safety of roflumilast was determined in predominantly 
ethnic Chinese patients.32 Three hundred and thirteen patients 
were randomized in a double-blind fashion to either roflumi-
last 500 μg or placebo. Roflumilast significantly increased 
FEV1 in these patients. The adverse effect rates were similar 
to those previously reported in the literature. These studies 
demonstrated that the efficacy of roflumilast is similar in the 
Asian compared to the Caucasian population.
A recent meta-analysis of roflumilast found a significant 
reduction in moderate-to-severe exacerbations and improve-
ment in pre-bronchodilator FEV1 compared to placebo.33 
However, the investigators did not find a significant reduction 
in severe exacerbations or mortality. 
In addition, the REACT study is an ongoing 1-year, 
Phase III/IV, randomized, double-blind, multicenter trial 
designed to investigate if roflumilast can further reduce 
exacerbation rates and improve lung function when added to 
a fixed combination of LABA and ICS.34 Roflumilast’s role 
in high-risk patients may be further defined by the results 
of this study. This study may provide further information 
on the quality of life issue in the vulnerable population or 
patients with high risk.
Cost-effectiveness 
The cost-effectiveness of roflumilast was evaluated in three 
different studies conducted in the United Kingdom. The first 
cost-effectiveness study of roflumilast was in 1,505 patients 
with severe or very severe COPD. This study analyzed data 
from a 1-year, randomized, placebo-controlled, double-blind, 
multinational trial of roflumilast 500 μg once daily.35 There 
were 159 centers from 14 countries included in this trial. 
Costs were analyzed from a societal perspective and included Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
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direct health care costs and productivity losses due to absence 
from work. The study also assessed the total number of 
patients with an improvement of a minimum of four units 
on the St George’s Respiratory Questionnaire (SGRQ) score 
and the incremental cost associated with the difference in the 
number of moderate-to-severe exacerbations. Estimated costs 
were derived from 2004 UK pricing. Total COPD-related 
costs were £1,636.74 (approximately US$2,261.32) for roflu-
milast compared to £1,401.16 (US$1,935.84) for placebo. 
There was a 0.05-unit (95% CI: −0.05 to 0.15) increase in 
the number of patients with a 4-unit improvement of the 
SGRQ total score. As well, the mean number of moderate or 
severe exacerbations decreased by 0.10 (95% CI: −0.05 to   
0.26), or 9%, which was not statistically significant. The cost 
avoided per exacerbation and the cost per clinically relevant 
improvement in SGRQ was £2,356 (US$3,255) and £4,712 
(US$6,510), respectively. A subgroup analysis of patients 
with very severe COPD showed net cost savings compared 
to placebo. This study is limited, as roflumilast was only 
compared to placebo and the overall rate of exacerbations 
was low, which might have underestimated roflumilast’s 
ability to lower exacerbations rates. 
The second cost-effectiveness study evaluated patients 
with severe COPD being treated with various combinations 
of a long-acting muscarinic antagonist, a LABA, an ICS, 
and roflumilast.36 The study defined efficacy as the relative 
rate ratios of COPD exacerbations. Costs were calculated 
from the perspective of the UK National Health Service and 
included total costs. Patients able to take ICS were analyzed 
separately from those who were unwilling or intolerant to 
ICS. Long-acting muscarinic antagonist was shown to be 
more cost-effective as initial treatment for patients tolerant 
to ICS. LAAC + LABA/ICS was more cost-effective than 
LABA/ICS + roflumilast in those who required additional 
therapy due to exacerbations. Among patients in the ICS-
intolerant group, LABA or LAAC was preferred as initial 
therapy. Among patients who were intolerant to ICS and still 
experiencing exacerbations, LABA + LAAC was preferred 
over LABA + LAAC + roflumilast. 
The third study determined the cost-effectiveness of 
adding roflumilast to LABA in patients with severe-to-very 
severe COPD.37 The investigators found that concomitant 
use of roflumilast with LABA increased quality-adjusted 
life years from 5.45 to 5.61 (0.16 [95% CI: 0.02–0.31] 
quality-adjusted life years gained) at a cost of £3,197 (95% 
CI: 2,135–4,253) or 5,408.63 (95% CI: 3,611.96–7,195.16) 
in US dollars.
Treatment options based on GOLD guidelines for patients 
with severe and very severe COPD include the addition of ICS 
to LABA either with or without an LAAC.38 Average wholesale 
prices for a 30-day supply of ICS include $135 for fluticasone 
and $152 for budesonide.39 Average wholesale prices for a 
30-day supply of long-acting bronchodilators include $157 for 
salmeterol, $265 for formoterol, and $337 for tiotropium. The 
actual wholesale price per unit of roflumilast is US$9.40, which 
translates to US$282 for a 30-day supply of therapy.
Place in therapy 
Roflumilast has been shown to be effective in improving 
lung function and decreasing COPD exacerbations which 
are typically associated with the vulnerable patient popula-
tion. However, it is important to consider both the pros and 
cons of roflumilast to determine its role in COPD treatment. 
Unlike most COPD therapies, roflumilast is available as an 
oral tablet, which may improve adherence in these patients. 
However, roflumilast has several disadvantages, including 
potential for drug interactions, adverse effects, and high cost, 
which may limit its use. Additionally, roflumilast is associ-
ated with weight loss and psychiatric events and is contrain-
dicated in moderate-to-severe hepatic impairment. Cost is an 
important limitation, as roflumilast is more expensive than 
ICS and LABA. All of these factors need to be considered 
when weighing the risks and benefits of starting roflumilast 
in each patient.
Conclusion
Roflumilast was shown to be safe and effective in several 
Phase III, randomized, double-blind, and placebo-controlled 
multicenter trials in different ethnic populations. In general, 
roflumilast appears to be useful in vulnerable patients with 
moderate-to-severe disease who are at high risk for exacer-
bations. However, the risks and benefits must be weighed 
when initiating roflumilast. 
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